Literature DB >> 11801560

Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents.

Cristina Rodríguez-Burford1, Mack N Barnes, Denise K Oelschlager, Russell B Myers, Lynya I Talley, Edward E Partridge, William E Grizzle.   

Abstract

PURPOSE: Nonsteroidal anti-inflammatory agents may inhibit carcinogenesis in specific tissues including the colon, breast, and pancreas, and, hence, may prove to be effective chemopreventive agents. The purpose of this study was to investigate the cellular effects of acetylsalicylic acid (ASA), acetaminophen, and a COX-2 inhibitor (NS-398) on the growth of cell lines of human ovarian cancer in vitro. EXPERIMENTAL
DESIGN: SK-OV-3, Caov-3, and NIH:OVCAR-3 ovarian carcinoma cell lines were treated with ASA (10(-6) M-10(-2) M), acetaminophen (10(-6) M-10(-2) M), and a COX-2 inhibitor (10(-6) M-10(-4) M) for 96 h. The number of viable cells was determined using a tetrazolium conversion assay. Immunohistochemical assessment was performed for alterations in expression of Ki-67, erbB-2, COX enzyme, and apoptosis in primary ovarian cancer cells using terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling assay.
RESULTS: A decrease in cell number compared with controls was observed for all of the cell lines treated with ASA, acetaminophen, and COX-2 inhibitor by cell count and tetrazolium conversion assay. A significant decrease in Ki-67 compared with controls in the OVCAR-3 (P = 0.005) and SK-OV-3 (P = 0.007) cell lines after treatment with the COX-2 inhibitor was observed. We observed a decrease in mitotic activity compared with controls in each cell line after treatment with the COX-2 inhibitor. Apoptosis was observed in primary ovarian cancer cell culture treated with COX-2 inhibitor.
CONCLUSION: Our results suggest additional study for the use of nonsteroidal anti-inflammatory agents, specifically COX-2 inhibitors, as a strategy of chemoprevention for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801560

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

1.  Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort.

Authors:  Veronica Wendy Setiawan; Rayna K Matsuno; Galina Lurie; Lynne R Wilkens; Michael E Carney; Brian E Henderson; Laurence N Kolonel; Marc T Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-04       Impact factor: 4.254

2.  Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis.

Authors:  Stefanos Bonovas; Kalitsa Filioussi; Nikolaos M Sitaras
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

3.  Use of common analgesics is not associated with ovarian cancer survival.

Authors:  Albina N Minlikeeva; Jo L Freudenheim; Wei-Hsuan Lo-Ciganic; Kevin H Eng; Grace Friel; Brenda Diergaarde; Francesmary Modugno; Rikki Cannioto; Emily Gower; J Brian Szender; Kassondra Grzankowski; Kunle Odunsi; Roberta B Ness; Kirsten B Moysich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-10       Impact factor: 4.254

4.  EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.

Authors:  Bastian Czogalla; Christina Kuhn; Sabine Heublein; Elisa Schmöckel; Doris Mayr; Thomas Kolben; Fabian Trillsch; Alexander Burges; Sven Mahner; Udo Jeschke; Anna Hester
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-04       Impact factor: 4.553

5.  Translational pathology of neoplasia.

Authors:  William E Grizzle; Sudhir Srivastava; Upender Manne
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

6.  The effects of different concentrations of acetylsalicylic acid on proliferation and viability of lymphocytes in cell culture.

Authors:  Tanja Dujić; Adlija Causević; Maja Malenica
Journal:  Bosn J Basic Med Sci       Date:  2008-08       Impact factor: 3.363

7.  Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer.

Authors:  Bin Su; Michael V Darby; Robert W Brueggemeier
Journal:  J Comb Chem       Date:  2008-04-02

Review 8.  Cyclooxygenase-2: a novel target in human solid tumors.

Authors:  Maria Rosaria Raspollini; Gian Luigi Taddei
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

9.  Preservation of immunorecognition by transferring cells from 10% neutral buffered formalin to 70% ethanol.

Authors:  D Otali; Q He; C R Stockard; W E Grizzle
Journal:  Biotech Histochem       Date:  2013-01-23       Impact factor: 1.718

10.  Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.

Authors:  Stephen H Bush; Sharon Tollin; Douglas C Marchion; Yin Xiong; Forough Abbasi; Ingrid J Ramirez; Nadim Bou Zgheib; Bernadette Boac; Patricia L Judson; Hye Sook Chon; Robert M Wenham; Sachin M Apte; Christopher L Cubitt; Anders E Berglund; Laura J Havrilesky; Johnathan M Lancaster
Journal:  Mol Clin Oncol       Date:  2016-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.